Physician profile
Mark Patrick Manning
NPI 1417439647
$6,213.87
in general payments reported to CMS, 2019-2025
36 companies · $926 in 2025
The $926 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,161 · 2022: $1,637 · 2023: $715 · 2024: $775 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.77 |
| Education | $190.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.73 | 2021-2023 | |
| Novo Nordisk INC | $526.73 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $462.30 | 2021-2025 | Spravato, Invega Sustenna |
| Amgen INC. | $441.04 | 2021-2023 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals Lp | $439.95 | 2021-2023 | Bevespi Aerosphere, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $390.72 | 2021-2025 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $381.69 | 2021-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $282.46 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.72 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $249.08 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $229.94 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $207.48 | 2021-2023 | |
| Gilead Sciences, INC. | $176.14 | 2021-2023 | |
| Boston Scientific Corporation | $152.26 | 2021-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.79 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $118.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $99.94 | 2021-2023 | |
| Tactile Systems Technology INC | $72.71 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.01 | 2023 | Xifaxan |
| Pfizer INC. | $60.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.14 | 2021-2022 | |
| Eisai INC. | $44.23 | 2021-2022 | |
| Antares Pharma, INC. | $40.78 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.47 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $34.18 | 2021 | |
| Harmony Biosciences LLC | $32.67 | 2024 | |
| Therapeuticsmd, INC. | $28.14 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $26.19 | 2021 | |
| Insulet Corporation | $23.21 | 2023 | Omnipod |
| Abbott Laboratories | $23.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.99 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.71 | 2022 | |
| Hologic Sales and Service, LLC | $18.57 | 2023 | Thinprep 2000 Processor, Aptima |
| Seqirus USA INC | $13.35 | 2021 | |
| Si-Bone, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.